1
|
Vervoordeldonk MYL, Hengeveld PJ, Levin MD, Langerak AW. B cell receptor signaling proteins as biomarkers for progression of CLL requiring first-line therapy. Leuk Lymphoma 2024; 65:1031-1043. [PMID: 38619476 DOI: 10.1080/10428194.2024.2341151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2024] [Accepted: 04/03/2024] [Indexed: 04/16/2024]
Abstract
The molecular landscape of chronic lymphocytic leukemia (CLL) has been extensively characterized, and various potent prognostic biomarkers were discovered. The genetic composition of the B-cell receptor (BCR) immunoglobulin (IG) was shown to be especially powerful for discerning indolent from aggressive disease at diagnosis. Classification based on the IG heavy chain variable gene (IGHV) somatic hypermutation status is routinely applied. Additionally, BCR IGH stereotypy has been implicated to improve risk stratification, through characterization of subsets with consistent clinical profiles. Despite these advances, it remains challenging to predict when CLL progresses to requiring first-line therapy, thus emphasizing the need for further refinement of prognostic indicators. Signaling pathways downstream of the BCR are essential in CLL pathogenesis, and dysregulated components within these pathways impact disease progression. Considering not only genomics but the entirety of factors shaping BCR signaling activity, this review offers insights in the disease for better prognostic assessment of CLL.
Collapse
MESH Headings
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Receptors, Antigen, B-Cell/metabolism
- Receptors, Antigen, B-Cell/genetics
- Signal Transduction
- Disease Progression
- Biomarkers, Tumor/genetics
- Prognosis
Collapse
Affiliation(s)
- Mischa Y L Vervoordeldonk
- Department of Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
| | - Paul J Hengeveld
- Department of Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
- Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands
| | - Mark-David Levin
- Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands
| | - Anton W Langerak
- Department of Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
| |
Collapse
|
2
|
Khan S, Molica S, Allsup D. Immunomodulation mediated by polyclonal IgG replacement in patients with CLL may be important in infection prevention. Hematol Oncol 2022; 40:528-529. [PMID: 35488852 DOI: 10.1002/hon.3011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
We read with interest the article by Idanna Innocenti and colleagues where a fixed dose of 10g hyaluronidase-free SCIg (subcutaneous immunoglobulin IgG) was administered every two weeks for one year to 10 patients with chronic lymphocytic leukaemia (CLL) and was highly effective in preventing infections [1]. It is generally accepted that frequency of infusions with hyaluronidase-free SCIg preparations are once weekly to maintain 'adequate' trough IgG [2], but this has been extrapolated from use in primary immunodeficient patients who typically have a complete antibody deficiency in contrast to the deficit observed in CLL This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Sujoy Khan
- Department of Immunology & Allergy, Castle Hill Hospital, Hull University Teaching Hospital NHS Trust, Cottingham, HU16 5JQ, United Kingdom
| | - Stefano Molica
- Department of Haematology, Castle Hill Hospital, Hull University Teaching Hospital NHS Trust, Cottingham, HU16 5JQ, United Kingdom
| | - David Allsup
- Department of Haematology, Castle Hill Hospital, Hull University Teaching Hospital NHS Trust, Cottingham, HU16 5JQ, United Kingdom.,Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Cottingham, Hull, HU6 7RX, United Kingdom
| |
Collapse
|
3
|
Bosch R, Mora A, Cuellar C, Ferrer G, Gorlatov S, Nomdedéu J, Montserrat E, Sierra J, Rai KR, Chiorazzi N, Moreno C. FcγRIIb-BCR coligation inhibits BCR signaling in chronic lymphocytic leukemia. Haematologica 2021; 106:306-309. [PMID: 32336680 PMCID: PMC7776347 DOI: 10.3324/haematol.2019.245795] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Rosa Bosch
- Laboratory of Oncology/Hematology and Transplantation, IIB Sant Pau, Barcelona
| | - Alba Mora
- Laboratory of Oncology/Hematology and Transplantation, IIB Sant Pau, Barcelona
| | - Carolina Cuellar
- Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona
| | - Gerardo Ferrer
- Karches Center for Oncology Research, The Feinstein Institute for Medical Research
| | | | - Josep Nomdedéu
- Laboratory of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona
| | | | - Jorge Sierra
- Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona
| | - Kanti R Rai
- Karches Center for Oncology Research, The Feinstein Institute for Medical Research
| | - Nicholas Chiorazzi
- Karches Center for Oncology Research, The Feinstein Institute for Medical Research
| | - Carol Moreno
- Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona
| |
Collapse
|
4
|
Ferrer G. Immunoglobulin replacement therapy targeting the BCR in chronic lymphocytic leukemia. EBioMedicine 2018; 36:7-8. [PMID: 30219356 PMCID: PMC6197750 DOI: 10.1016/j.ebiom.2018.09.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2018] [Accepted: 09/07/2018] [Indexed: 11/29/2022] Open
Affiliation(s)
- Gerardo Ferrer
- Laboratory of Experimental Immunology, Karches Center for Oncology Research, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, USA.
| |
Collapse
|
5
|
Spaner DE, Venema R, Huang J, Norris P, Lazarus A, Wang G, Shi Y. Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia. EBioMedicine 2018; 35:222-232. [PMID: 30174282 PMCID: PMC6156707 DOI: 10.1016/j.ebiom.2018.08.045] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2018] [Revised: 08/14/2018] [Accepted: 08/20/2018] [Indexed: 11/16/2022] Open
Abstract
The intrinsic humoral immunodeficiency of chronic lymphocytic leukemia (CLL) is often managed with immunoglobulin replacement therapy (IgRT) to maintain IgG levels in the low-normal range (6–8 g/L) but optimal targets for IgG and timing to commence IgRT are unclear. IgG levels fell near 6 g/L at rates of −0.85±0.14 g/L/year in 51 patients who required treatment for CLL within 4.5±0.4 years from initial diagnosis and − 0.27±0.04 g/L/year in 40 patients with progressive disease who remained untreated after 8.5±0.5 years. In contrast, endogenous IgG levels remained above 8 g/L in patients with highly indolent disease (n = 25) and TNFα and beta-2-microglobulin (β2M) in blood decreased when IgRT was used to increase IgG levels over 9 g/L. At 15 g/L but not 5 g/L, the IgRT product Hizentra® inhibited B cell receptor (BCR)-activation, TNFα production, and survival in vitro, particularly of CLL cells that spontaneously made little TNFα. These findings suggest deterioration of the humoral immune system is associated with progressive CLL and altering the dosing of IgRT to achieve higher than conventional IgG target levels may have therapeutic activity. Immunoglobulin levels decline at rates that reflect the clinical course of CLL. IgG levels over 10 g/L achieved with replacement therapy are associated with evidence of disease control in vivo and inhibition of BCR-mediated activation of CLL cells in vitro. Monitoring rates of decline of Ig levels in CLL patients gives biological information on disease severity. Appropriate IgG target levels for immunoglobulin replacement therapy in CLL may be much higher than for patients with other immunodeficiencies.
Collapse
Affiliation(s)
- David E Spaner
- Biology Platform, Sunnybrook Research Institute, Toronto M4N 3M5, Canada; Dept. of Immunology, University of Toronto, Toronto M5S 1A8, Canada; Dept. of Medical Biophysics, University of Toronto, Toronto M5G 2M9, Canada; Sunnybrook Odette Cancer Center, Toronto M4N 3M5, Canada; Dept. of Medicine, University of Toronto, Toronto M5G 2C4, Canada.
| | - Robertson Venema
- Biology Platform, Sunnybrook Research Institute, Toronto M4N 3M5, Canada
| | - Justin Huang
- Biology Platform, Sunnybrook Research Institute, Toronto M4N 3M5, Canada
| | - Peter Norris
- Keenan Research Center, St. Michael's Hospital, Toronto M5B 1T8, Canada; Dept. of Laboratory Medicine and Pathobiology, University of Toronto, M5S 1A1, Canada
| | - Alan Lazarus
- Keenan Research Center, St. Michael's Hospital, Toronto M5B 1T8, Canada; Dept. of Laboratory Medicine and Pathobiology, University of Toronto, M5S 1A1, Canada
| | - Guizhi Wang
- Biology Platform, Sunnybrook Research Institute, Toronto M4N 3M5, Canada
| | - Yonghong Shi
- Biology Platform, Sunnybrook Research Institute, Toronto M4N 3M5, Canada
| |
Collapse
|
6
|
Liu QM, Xie CL, Gao YY, Liu B, Lin WX, Liu H, Cao MJ, Su WJ, Yang XW, Liu GM. Deep-Sea-Derived Butyrolactone I Suppresses Ovalbumin-Induced Anaphylaxis by Regulating Mast Cell Function in a Murine Model. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2018; 66:5581-5592. [PMID: 29763312 DOI: 10.1021/acs.jafc.8b01674] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Deep-sea-derived butyrolactone I (BTL-I), which was identified as a type of butanolide, was isolated from Aspergillus sp. Ovalbumin (OVA)-induced BALB/c anaphylaxis was established to explore the antifood allergic activity of BTL-I. As a result, BTL-I was able to alleviate OVA-induced allergy symptoms, reduce the levels of histamine and mouse mast cell proteinases, inhibit OVA-specific IgE, and decrease the population of mast cells in the spleen and mesenteric lymph nodes. BTL-I also significantly suppressed mast-dependent passive cutaneous anaphylaxis. Additionally, the maturation of bone marrow-derived mast cells (BMMCs) declined as BTL-I caused down-regulation of c-KIT receptors. Furthermore, molecular docking analyses revealed that BTL-I interacted with the inhibitory receptor, FcγRIIB. In conclusion, the reduction of mast cell function by deep-sea-derived BTL-I as well as its interactions with the inhibitory receptor, FcγRIIB, may contribute to BTL-I-related protection against food anaphylaxis.
Collapse
Affiliation(s)
- Qing-Mei Liu
- College of Food and Biological Engineering, Xiamen Key Laboratory of Marine Functional Food, Fujian Provincial Engineering Technology Research Center of Marine Functional Food, Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources , Jimei University , 43 Yindou Road , Xiamen , 361021 Fujian , P.R. China
| | - Chun-Lan Xie
- Key Laboratory of Marine Biogenetic Resources, South China Sea Bio-Resource Exploitation and Utilization Collaborative Innovation Center , Third Institute of Oceanography, State Oceanic Administration , 184 Daxue Road , Xiamen , 361005 Fujian , P.R. China
| | - Yuan-Yuan Gao
- College of Food and Biological Engineering, Xiamen Key Laboratory of Marine Functional Food, Fujian Provincial Engineering Technology Research Center of Marine Functional Food, Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources , Jimei University , 43 Yindou Road , Xiamen , 361021 Fujian , P.R. China
| | - Bo Liu
- College of Food and Biological Engineering, Xiamen Key Laboratory of Marine Functional Food, Fujian Provincial Engineering Technology Research Center of Marine Functional Food, Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources , Jimei University , 43 Yindou Road , Xiamen , 361021 Fujian , P.R. China
| | - Wei-Xiang Lin
- Key Laboratory of Marine Biogenetic Resources, South China Sea Bio-Resource Exploitation and Utilization Collaborative Innovation Center , Third Institute of Oceanography, State Oceanic Administration , 184 Daxue Road , Xiamen , 361005 Fujian , P.R. China
| | - Hong Liu
- College of Food and Biological Engineering, Xiamen Key Laboratory of Marine Functional Food, Fujian Provincial Engineering Technology Research Center of Marine Functional Food, Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources , Jimei University , 43 Yindou Road , Xiamen , 361021 Fujian , P.R. China
| | - Min-Jie Cao
- College of Food and Biological Engineering, Xiamen Key Laboratory of Marine Functional Food, Fujian Provincial Engineering Technology Research Center of Marine Functional Food, Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources , Jimei University , 43 Yindou Road , Xiamen , 361021 Fujian , P.R. China
| | - Wen-Jin Su
- College of Food and Biological Engineering, Xiamen Key Laboratory of Marine Functional Food, Fujian Provincial Engineering Technology Research Center of Marine Functional Food, Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources , Jimei University , 43 Yindou Road , Xiamen , 361021 Fujian , P.R. China
| | - Xian-Wen Yang
- Key Laboratory of Marine Biogenetic Resources, South China Sea Bio-Resource Exploitation and Utilization Collaborative Innovation Center , Third Institute of Oceanography, State Oceanic Administration , 184 Daxue Road , Xiamen , 361005 Fujian , P.R. China
| | - Guang-Ming Liu
- College of Food and Biological Engineering, Xiamen Key Laboratory of Marine Functional Food, Fujian Provincial Engineering Technology Research Center of Marine Functional Food, Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources , Jimei University , 43 Yindou Road , Xiamen , 361021 Fujian , P.R. China
| |
Collapse
|